January 10, 2012

Industry-Academia Collaboration Workshop on Process and Strategy in Biotechnology Innovation 2009.3.10


■ Industry-Academia Collaboration Workshop on Process and Strategy in Biotechnology  Innovation

March 10, 2009 at Roppongi Academy Hills 49F, Tokyo
Organized by IIR
Supported by Japan Bioindustry Association (JBA)
Japan Pharmaceutical Manufacturers Association (Office of Pharmaceutical Industry Research (OPIR))
New Energy and Industrial Technology Development Organization (NEDO)

Opening Address
Seiichiro Yonekura (IIR)

Session I: Government Support to the Commercialization of Scientific Discovery
Chair: Sadao Nagaoka (IIR)

Keynote Speech 1: “Lessons from NIH SBIR Program”
  Charles Wessner (US National Academies)
  Comment: Katsushi Takehiro (Ministry of Economy, Trade and Industry)

Session II: Bio-based Innovation—Issues as Seen from the Industry
Chair: Kentaro Nobeoka (IIR)

Keynote Speech 2:“Exploiting the Biotechnology for Pharmaceutical Industry in Japan”
  Hiroshi Akimoto (University of Tokyo / Kyushu University / JPMA)

Keynote Speech 3: “Opportunities and Barriers to Biotechnology Firm Growth in Japan”
  Ichiro Nakatomi (NanoCarrier Co., Ltd.)
  Comment: Gensuke Tokoro (aRigen Pharmaceuticals, Inc.)
        Yaichi Aoshima (IIR)

Session III: Mechanism of Commercialization of Biotechnology—Bio-startups and Alliance (Report
of the findings of joint research)
Chair: Hiroyuki Chuma (IIR)

(1) “Strategic Alliance as an Alternative Strategy for Bio-ventures”
  Seiichiro Yonekura and Eyo Shiaw Jia (IIR)
      Comment: Kiyokazu Yamazaki (Ichiyoshi Research Institute Inc.)
(2) “Entry and Growth Performance of the Japanese Biotechnology Industry”
Sadao Nagaoka (IIR), Yuji Honjo (Chuo University / IIR), Kenta Nakamura (Kobe University /
  IIR), Setsuo Morishita (JBA) and Yumi Shimizu (JBA)
      Comment: Akihiko Shimauchi (M’s Science Corporation)
(3) “Alliance Strategy and Performance of Major Pharmaceutical Firms in US, Europe and Japan”
  Sadao Nagaoka, Kenta Nakamura, Yuji Honjo, Toshiro Takashima (OPIR)
      Comment:  Masayuki Tsuchiya (Chugai Pharmaceutical Co., Ltd.)
Closing Remarks:
Setsuo Morishita